Lysogene’s Board of Directors is composed of accomplished leaders from the healthcare industry who bring their expertise in science, drug development, commercialization and strategy to developing and expanding our gene therapy programs.
Annette V. Clancy is Chair of Lysogene's Board of Directors.
Ms Clancy has over 15 years’ experience in business development having served as Head of Global Transactions and Alliance Management at GlaxoSmithKline (GSK) up until 2008 where she was responsible for executing innovative deals ranging from early drug discovery partnerships, to global commercial alliances and mergers and acquisitions. Prior to her role in business development, Ms. Clancy held a number of positions in clinical research, R&D project management and commercialization within GSK, developing a broad range of commercial and business expertise. Ms. Clancy is currently Senior European Advisor to the life science team of Frazier Healthcare. In addition to this role, Ms. Clancy has held a number of non-executive board positions on private and public European biotech companies and she currently serves as Chair of the Board at Genable Technologies Ltd (Ireland) and Obseva Ltd (Switzerland) and is a Non-Executive Director on the Board of SOBI Inc (Sweden).
Ms. Clancy has a B.Sc. (Hons) Pharmacology from Bath University and is based in London, UK.
Philippe Goupit is a non-Executive, independent member of Lysogene’s Board of Directors.
Philippe graduated from the Paris School of Pharmacy and held several key positions in sales, marketing and regulatory affairs at Servier and then at Pasteur in the vaccines sector. Subsequently, he was appointed VP, Mergers & Acquisitions at Sanofi, a global leader in the healthcare sector. He was also Head of Investor Relations at the Sanofi group for several years. Philippe currently sits on the Board of Directors of MedDay Pharmaceuticals, a pioneer in developing therapies for central nervous system disorders.
David Schilansky is a non-Executive, independent member of Lysogene’s Board of Directors.
Mr. Schilansky, currently Deputy CEO and Chief Operating Officer of DBV Technologies (Euronext: DBV; NASDAQ: DBVT), has 20 years of leadership experience in the field of biotechnology and finance. DBV Technologies is a late clinical-stage specialty biopharmaceutical company, for which Mr. Schilansky oversees the company’s strategic implementation. He was appointed to this role in January 2015 after serving as the Chief Financial Officer from 2011. He is a member of DBV Technologies’ Executive Committee. Previously, Mr. Schilansky held various senior positions at Ipsen Pharma, including Interim Chief Financial Officer. Earlier in his career, he worked at Thomson Inc. (now Technicolor S.A.) as co-head of investor relations and at Warburg Dillon Read (now UBS) in mergers and acquisitions.
Mr. Schilansky received a master’s degree from the University of Paris Dauphine and a post-graduate degree from the Imperial College London.
Mr Peter Lichtlen is a non-Executive, independent member of Lysogene's Board of Directors.
Dr. Peter Lichtlen was Chief Medical Officer at Sucampo Pharmaceuticals Inc. until the company’s acquisition by Mallinckrodt Pharmaceuticals earlier this year and has 18 years of leadership experience in the field of biotechnology.
Prior to joining Sucampo, Dr. Lichtlen was at ESBATech AG (acquired by Alcon/Novartis in 2009), which he joined in 2000. At ESBATech, Dr. Lichtlen served as Medical Director/Head Clinical Research and Development and was a member of its senior management team, from 2004 to 2010. Dr. Lichtlen also co-founded Numab AG, a Swiss biotechnology company that develops antibody-based therapeutics, where he remains a member of the Board of Directors and Chief Medical Officer. Dr. Lichtlen also currently serves on the scientific advisory board of Apidel SA, a drug delivery company.
Dr. Lichtlen is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP), the author of various peer-reviewed articles, and the holder of several patents. Dr. Lichtlen earned a Bachelor’s Degree in business administration, and doctorate degrees in medicine and molecular biology at the University of Zurich.